Pharmaceutical Industry 6 – 12 Apr: Ft Biogen, Viridian Therapeutics and UCB
- Biogen has secured US FDA approval for a high dose Spinraza regimen for spinal muscular atrophy.
- Viridian Therapeutics has reported encouraging phase 3 REVEAL-1 results for elegrobart in active thyroid eye disease.
- UCB has won European Commission approval for Kygevvi, the first authorised treatment for thymidine kinase 2 deficiency.
A strong week for specialist medicine
Three separate developments from Biogen, Viridian Therapeutics and UCB have underlined an important truth about the pharmaceutical industry: some of the most meaningful advances are happening in highly specialised areas where patient need has long outpaced treatment options.
From spinal muscular atrophy and thyroid eye disease to thymidine kinase 2 deficiency, each announcement points to a different kind of progress.
In one case, an established therapy is being strengthened through dose optimisation. In another, a late-stage pipeline candidate is showing promise as a more convenient alternative to existing care. In the third, an ultra-rare condition has finally received an approved treatment beyond supportive management.
Taken together, the news reflects a sector that is not merely chasing novelty, but refining science in ways that may materially improve outcomes for patients and their families.
Biogen builds on a decade of SMA progress with High Dose Spinraza
Biogen’s latest milestone comes in the form of US Food and Drug Administration approval for a new high dose regimen of Spinraza for the treatment of spinal muscular atrophy, or SMA.
The approved regimen includes 50mg and 28mg doses, designed to deliver a higher concentration of the medicine during both the loading and maintenance phases of treatment.
This is not a minor tweak dressed up as a breakthrough. Rather, it is a strategic effort to enhance a therapy that has already reshaped the SMA landscape over the past decade.
Spinraza has long been one of the landmark treatments in the field, and Biogen’s decision to pursue a higher dose regimen speaks to a maturing phase of pharmaceutical development: improving what already works.
The approval is based on data from the phase 2/3 Devote study, which evaluated the efficacy and safety of the higher dose approach in both treatment-naïve patients and those who had previously received Spinraza.
According to Biogen, treatment-naïve infants receiving the high dose showed statistically significant improvements in motor function compared with a prespecified matched sham group.
That matters. In conditions such as SMA, where early intervention can shape the trajectory of a child’s development, gains in motor function are not abstract endpoints. They can translate into meaningful changes in everyday life.
Crucially, Biogen said the safety profile of the high dose regimen was generally consistent with the known safety of the low dose regimen, which will reassure clinicians and families weighing the benefits of dose intensification against tolerability concerns.
The new regimen is expected to become available in the United States in the coming weeks and has already been approved in the European Union, Switzerland and Japan, giving it a growing international footprint.
Comments from across the SMA field suggest that this approval is being viewed as a serious step forward rather than a routine regulatory update. The Director of the Center for Experimental Neurotherapeutics at St Jude Children’s Research Hospital said that optimising the dose of nusinersen builds on a therapy already known to change lives, adding that High Dose Spinraza is likely to play an important role in the future of SMA care.
Biogen’s own Head of Development framed the approval as part of the company’s long-running commitment to learn, innovate and advance care for the SMA community. Cure SMA echoed that sentiment, describing the original approval of Spinraza almost a decade ago as a turning point, and today’s high dose approval as further progress in addressing unmet need.
Viridian Therapeutics strengthens its thyroid eye disease ambitions
Where Biogen is extending the life and reach of an established therapy, Viridian Therapeutics is advancing a newer contender with potentially significant commercial and clinical implications.
The company has reported encouraging topline results from REVEAL-1, its phase 3 clinical trial evaluating elegrobart in patients with active thyroid eye disease, or TED. The study compared two subcutaneous dosing schedules, every four weeks and every eight weeks, against placebo.
According to Viridian, both dosing regimens delivered clinically meaningful improvements in proptosis, with responder rates of 54% and 63%, compared with 18% for placebo at week 24.
More than half of patients receiving the four-week regimen also experienced complete resolution of diplopia, a particularly important finding in a condition that can affect both visual function and quality of life.
Viridian is understandably emphasising the practical significance of the administration route. The company says elegrobart is positioned as potentially the first subcutaneous autoinjector treatment for TED, which would mark a notable departure from the current marketed therapy, which requires eight intravenous infusions.
That distinction could prove highly significant if the treatment ultimately secures approval. In a market where current options have generated strong revenues despite limited uptake, convenience may be more than a lifestyle improvement; it may be a catalyst for wider patient adoption.
Viridian’s leadership has clearly identified this, pointing to the opportunity for an at-home, self-administered option that could expand access and reshape the treatment experience.
The Professor of Ophthalmology at Colorado University Anschutz added further weight to the results, noting that subcutaneous elegrobart showed rapid and clinically meaningful reductions in both proptosis and diplopia, alongside a well-tolerated and convenient dosing profile.
It is a reminder that innovation in pharmaceuticals is not always about inventing an entirely new class of medicine. Sometimes it is about making treatment more practical, less burdensome and more aligned with how patients want to live.
Viridian has also confirmed that REVEAL-2, its phase 3 study in chronic thyroid eye disease, remains on track for a topline readout in the second quarter of 2026, with a regulatory submission expected the following year. That means the company’s TED programme still has major inflection points ahead.
UCB delivers a historic first for the TK2 deficiency community
If Biogen’s news is about optimisation and Viridian’s is about convenience-led disruption, UCB’s approval of Kygevvi stands out for a different reason entirely: it gives a long-overlooked patient population an approved treatment where previously there was none.
The European Commission has approved Kygevvi as the first and only authorised treatment for thymidine kinase 2 deficiency, or TK2d, an ultra-rare and life-threatening mitochondrial disease associated with progressive muscle weakness.
The approval applies to paediatric and adult patients with genetically confirmed TK2d whose symptoms began at or before the age of 12.
UCB describes Kygevvi as a 2g/2g powder for oral solution, and importantly, the approval means patients in the European Union now have access to a therapy beyond supportive care.
In rare disease medicine, that phrase carries enormous weight. Supportive care can be vital, but it is not the same as having an approved treatment designed to address the biology of the disease itself.
UCB says Kygevvi is intended to support mitochondrial DNA maintenance in skeletal muscle, targeting a key biological driver of TK2d. The approval is supported by pooled data from two studies involving patients with symptom onset at or before age 12. Those trials assessed motor milestones, ventilatory and feeding support, and survival.
The results offer grounds for cautious optimism. Across the studies, 26 of 31 patients regained one or more motor milestones after treatment began. Changes in ventilatory and feeding support also suggested clinical benefit, with some patients able to discontinue support after starting therapy.
What’s more, Kygevvi was reported to be well tolerated, with the most common adverse reactions being diarrhoea, vomiting and abdominal pain.
UCB’s Chief Medical Officer called the approval a historic milestone for the TK2d community, while an Associate Professor of Medical Genetics at the University of Bologna described it as a long-awaited moment of hope for patients and families who have carried an enormous burden with remarkable resilience.
For clinicians in the rare disease space, this is the kind of development that reverberates beyond a single label. It signals that even the smallest patient populations are not beyond the reach of meaningful therapeutic progress.
What this means for pharmaceutical manufacturing and pharmaceutical production
These developments also carry broader implications for pharmaceutical manufacturing and pharmaceutical production.
New approvals and positive late-stage data do not simply affect prescribing decisions; they influence how companies plan supply, scale production and design future manufacturing strategies.
For Biogen, the rollout of a high dose Spinraza regimen introduces new considerations around production volumes, formulation logistics and market supply as the regimen becomes available in the United States and gains traction across already approved regions.
For Viridian Therapeutics, the prospect of a subcutaneous autoinjector treatment points toward manufacturing systems that prioritise device integration, patient convenience and scalable delivery formats suitable for at-home use.
For UCB, bringing the first approved therapy for an ultra-rare mitochondrial disease to the European market reinforces the growing importance of agile, specialised production capabilities for orphan medicines.
In short, this news reflects a pharmaceutical sector where manufacturing is becoming ever more closely tied to patient-centred innovation. The challenge is no longer just to make medicines at scale, but to produce the right therapies, in the right formats, for increasingly specific patient needs.
A pharmaceutical sector moving with purpose
There is a common thread running through the announcements from Biogen, Viridian Therapeutics and UCB: each company is responding to a clear gap in care, but doing so in a different way.
Biogen is refining a trusted therapy to potentially deliver stronger benefits in SMA. Viridian is pushing towards a more convenient and accessible model of care in thyroid eye disease. UCB is giving the TK2 deficiency community something it has never had before: an authorised treatment option beyond support alone.
For the pharmaceutical industry, this is a timely reminder that progress does not come in one uniform shape. Sometimes it looks like better dosing. Sometimes it looks like easier administration. Sometimes it looks like a long-awaited first approval in a neglected disease area.
Either way, the direction of travel is clear. Precision, practicality and persistence are increasingly defining the next chapter of pharmaceutical innovation.
Conclusion
Biogen, Viridian Therapeutics and UCB have each delivered news that speaks to the evolving strength of the pharmaceutical industry.
Whether through the FDA approval of High Dose Spinraza, the promising phase 3 performance of elegrobart, or the landmark European approval of Kygevvi, all three stories point to a sector working to improve not just treatment science, but also the lived experience of care.
For patients, clinicians and the wider world of pharmaceutical manufacturing and production, these are not isolated updates. They are signs of an industry continuing to move forward with sharper focus, deeper specialisation and a stronger sense of purpose.
News Credits:
FDA approves new high dose Spinraza regimen for SMA
Viridian reports positive results from elegrobart phase 3 trial
Kygevvi approved in Europe as first treatment for TK2d
Things you may also like: